Modulation of the subventricular zone (SVZ) neurogenic niche can enhance brain repair in several disorders including Parkinson's disease (PD). Herein, we used biocompatible and traceable polymeric nanoparticles (NPs) containing perfluoro-1,5-crown ether (PFCE) and coated with protamine sulfate to complex microRNA-124 (miR-124), a neuronal fate determinant. The ability of NPs to efficiently deliver miR-124 and prompt SVZ neurogenesis and brain repair in PD was evaluated. In vitro, miR-124 NPs were efficiently internalized by neural stem/progenitors cells and neuroblasts and promoted their neuronal commitment and maturation. The expression of Sox9 and Jagged1, two miR-124 targets and stemness-related genes, were also decreased upon miR-124 NP treatment. In vivo, the intracerebral administration of miR-124 NPs increased the number of migrating neuroblasts that reached the granule cell layer of the olfactory bulb, both in healthy and in a 6-hydroxydopamine (6-OHDA) mouse model for PD.
Introduction
Neurogenesis occurs constitutively in the subventricular zone (SVZ) of the adult mammalian brain, including in humans [1] . Within this region, neural stem cells (NSCs) can self-renew, proliferate and give rise to new neurons, astrocytes and oligodendrocytes. In rodents, newborn neurons generated in the SVZ migrate through the rostral migratory stream (RMS) towards the olfactory bulb (OB) where they fully differentiate as mature interneurons [2] . Adult neurogenesis homeostasis is altered in several brain disorders including Parkinson's disease (PD) [3] . PD is characterized by the loss of dopaminergic (DA) neurons present in the substantia nigra (SN) and degeneration of DA terminals in the striatum, leading to movement coordination impairments and cognitive deficits. Several factors have already been reported to improve functional recovery in PD animals models by increasing endogenous neurogenesis and migration of newly born neurons into the lesioned striatum [4, 5] . However, an efficient therapy aiming at full regeneration has not yet been found. Therefore, it is imperative to find new platforms to efficiently deliver pro-neurogenic factors to NSCs and to boost the endogenous regenerative capacity of adult brain.
A tightly controlled network of intrinsic and extrinsic signals, including small non-coding RNAs (e.g. microRNAs) [6] [7] [8] [9] regulate the neurogenic niche. MicroRNAs (miR) are able to regulate hundreds of genes [10] at the posttranscriptional level by inhibiting mRNA translation or inducing mRNA degradation [11] . MiR-124 is one of the most abundant miR in the adult brain [12] . The expression of miR-124 is initiated during the transition from NSC to progenitor cell and it is enhanced with neuronal maturation [13, 14] . Several studies have shown that the overexpression of miR-124 induces neuronal differentiation of both progenitor cells [15, 16] and HeLa cells [10] . More recently, lentiviral overexpression of the miR-124 precursor (among other factors) was capable of inducing the differentiation of human neonatal foreskin fibroblasts into functional mature neurons [17, 18] . In vivo, miR-124 overexpression in the SVZ niche increased the number of newborn neurons without affecting their migratory capability [13, 14] . Additionally, miR-124 is intimately associated with brain pathologies and neurodegenerative disorders, such as PD. Indeed, within the miR-124 validated targets, one-fourth are deregulated in PD (49 genes out of 202, MIRECORDS database) [19] . Significant decrease of miR-124 was described in the SN of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice (PD mouse model) as well as in MN9D dopaminergic neurons treated with methyl phenyl pyridinium (MPP) iodide, while its overexpression improved cell survival [20, 21] . Therefore, increasing miR-124 intracellular levels likely stands for a novel therapeutic strategy to improve functional outcome in PD (reviewed by Sun et al 2015 [3] ).
Due to the short half-life and poor stability of miR, their efficient delivery into cells in a safe and controlled way remains a challenge [22] . Viral vectors have a high capacity to deliver miR, however safety issues such as immunogenicity and the risk of triggering oncogenic transformation limits its translation potential [23] . Non-viral vectors such as polymeric nanoparticles (NPs), which avoid these safety issues, have been used by us and others to efficiently deliver proneurogenic molecules, including miR, into cells [7, [23] [24] [25] . As so, we hypothesized that the use of polymeric NPs to deliver miR-124 could promote neurogenesis of SVZ NSCs both in vitro and in vivo and ultimately promote brain repair. To confirm this hypothesis we used a NP formulation formed by poly(lactic acid-co-glycolic acid) (PLGA) and perfluoro-1,5-crown ether (PFCE), a fluorine compound that can be tracked non-invasively by 19 F-MRI, and coated with protamine sulfate to complex miR-124 [26] . The neurogenic potential of this NP formulation was assessed both in physiologic conditions and in a 6-hydroxydopamine (6-OHDA) mouse model for PD. We have found that miR-124-loaded NPs (miR-124 NPs) enhanced neuronal differentiation and axonogenesis in vitro. Accordingly, mRNA and protein levels of both Sox9 and Jagged1, two key non-neuronal genes, were also decreased upon miR-124 NP treatment. In vivo, a single administration of miR-124 NPs into the lateral ventricles of both healthy and 6-OHDA-lesioned mice was able to significantly increase the number of migrating neuroblasts that reached the granule cell layer of the OB. Importantly, miR-124 NPs also potentiated the migration of SVZderived new neurons towards the 6-OHDA lesioned striatum and decreased the motor impairments found in 6-OHDA treated mice. Altogether, our results support the therapeutic potential of miR-124 NPs as an enhancer of endogenous brain repair mechanisms.
Materials and Methods
Preparation of PLGA NPs.
PLGA NPs were prepared as described by Gomes and colleagues [26] . Briefly, PLGA solution (5% w/v in water) and stirred. NPs were centrifuged and washed with distilled water before freeze-drying. NPs were coated with protamine sulfate (PS) in 1:1 ratio by agitation at room temperature (RT). After this incubation period, NPs were dialyzed (MWCO of 50 kDa) against distilled water, frozen and lyophilized to obtain a dry powder that was stored in a desiccator at RT.
Complexation of NPs with miR and cell transfection.
NPs were weighed and sterilized under ultraviolet light before being resuspended in SVZ cell culture medium devoid of growth factors and sonicated (Transsonic T460/HH, Elma Schmidbauer GmbH, Singen, Germany). To this suspension (1 to 20 µg/mL final concentration, specified in the text) a total of 200 nM of miR (miR-124 or scramblemiR, both from GE Healthcare Dharmacon Inc., Chicago, USA) were added and allowed to complex for 45 min at 37 ºC with intermittent agitation ( Figure 1A ). Void
NPs were prepared using the same procedure but without adding miR. Cells were then incubated with void or miR-loaded NPs for 4 h at 37 ºC in an incubator with 5% CO2 and 95% atmospheric air. All miR are from GE Healthcare Dharmacon Inc. and were provided annealed, desalted and in the 2'-hydroxyl form and were resuspended in sterile RNA free water. MiR-124 mature sequence is 5'UAAGGCACGCGGUGAAUGCC3'.
Characterization of NPs.
Particle size and zeta potential of NP suspensions were determined using light scattering via a Zeta PALS zeta potential analyzer and ZetaPlus Particle Sizing Software (Brookhaven Instruments Corporation, NY, USA). Size measurements were performed at 25 ºC, and data were recorded at a 90º angle, with an equilibration time of 2.5 min and individual run times of 60 s. The average diameters described are number-weighted average diameters. The zeta potential of NPs was determined in aqueous solutions, at 25 ºC.
SVZ cell cultures and experimental treatments.
SVZ cell cultures were prepared from 1 to 3 day-old C57BL/6 mice as described by us [27] . Briefly, brains were removed and placed into HBSS solution supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin (all from Life Technologies, Carlsbad, CA, USA). SVZ fragments were dissected from 450 µm-thick coronal brain sections and digested in 0.025% trypsin, 0.265 mM EDTA (all from Life Technologies), followed by mechanical dissociation. The single cell suspension was diluted in serumfree medium (SFM) composed of Dulbecco's modified Eagle medium [(DMEM)/F12 + GlutaMAX™-l)] supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 1%
B27 supplement, 10 ng/mL epidermal growth factor (EGF), and 5 ng/mL basic fibroblast growth factor-2 (FGF)-2 (all from Life Technologies) and plated onto uncoated petri dishes (Corning Life Science, NY, USA) and allowed to develop in an incubator with 5% CO2 and 95% atmospheric air at 37 ºC. In these conditions, SVZ cells grow in suspension and generate neurospheres that are rich in neural and progenitor stem cells at distinct stages of differentiation and with proliferative and selfrenewing abilities, as previously shown by us [7, 24, [27] [28] [29] [30] . Five to six-day-old neurospheres were seeded onto 0.1 mg/mL poly-D-lysine-(PDL; Sigma-Aldrich Co. Zeiss, Jena, Germany).
PI incorporation.
SVZ cells were treated with NPs and maintained in culture for 48 h after transfection. previously reported by us [7, 25] .
In vivo studies.
All animal experimental procedures were performed in accordance with institutional injected into the lateral ventricle of mice as described above and 24 h after injection the mice were euthanized.
Apomorphine-induced rotation test.
At week 2 post-stereotaxic injections, the mice received in the neck a subcutaneous injection of 0.5mg/kg of apomorphine hydrochloride (Sigma) dissolved in 1% ascorbic acid and 0.9% NaCl. Mice were placed in round testing bowls for 45 min and their behavior was recorded using a digital camera. Number of net contralateral turns = contralateral turns -ipsilateral turns; data are presented as percentage of 6-OHDA saline mice.
Immunohistochemistry.
Mice were deeply anesthetized with a mixture of ketamine and xylazine, and then perfused intracardially with saline solution followed by 4% PFA. Brains were surgically removed and post-fixed with 4% PFA for 24 h, followed by immersion in a 30%
sucrose solution (Fisher Scientific) until sunk. Thereafter, brains were cryopreserved and 40 µm-thick coronal sections from the olfactory bulb (OB) or SVZ/striatum regions were collected in series of six slices (spaced 240 µm from each other), using a cryostat (CM 3050S, Leica Microsystems, Wetzlar, Germany). Immunostaining of tissue sections was performed by adapting the experimental protocol described elsewhere [32] . 
Statistical analysis.
Analysis of immunocytochemistry experiments were performed at the border of seeded neurospheres, where cells formed a pseudo-monolayer. The experiments were performed in three independent cultures, unless stated otherwise, and for each experimental condition at least 2 coverslips were assayed per culture. the SVZ, OB (granule (GCL) and glomerular (GL) layers) and striatum of at least 3 animals, as described previously by us [8] . Figure 1D arrowhead). The development of efficient and safer delivery systems for miR is a major concern, since naked miR delivery presents a poor uptake efficiency caused mainly by miR hydrophilic nature and negative charge [22, 23] . Our NP formulation proved to be efficient in both delivery and protection of miR. In fact,
we showed recently that the same NP formulation was able to rapidly release miR in human umbilical vein endothelial cells (HUVEC), with only 50% of miRDy547 co-localizing with FITC-NPs at 24 h post-transfection [26] . Moreover, the retention of about 30% of NPs or miR-Dy547 within the endolysossomal compartments was associated with the ability of the NP formulation to present miR to the RNA-induced silencing complex (RISC) machinery. This characteristic culminated in a higher biologic effect than the commercial transfection system SIPORT, either in normoxia or hypoxia conditions [26] . In Importantly, our formulation was efficiently internalized and able to deliver miR-124 into stem/progenitor and immature cells, the cell population that in response to increased levels of miR-124 may differentiate into mature neurons. In accordance, internalization in mature neurons was not analyzed due to its already high basal expression of miR-124 [13] . 
miR-124 NPs prompt neuroblasts proliferation
Next, we examined the effect of miR-124 NPs in cell proliferation by analyzing 5-bromo-2'-deoxyuridine (BrdU) and Ki67 staining 48 h after cell treatments.
BrdU is a marker for cells undergoing S phase of the cell cycle, while all cycling cells (G1, S, G2 and M phases) express the Ki67 marker. Overall, total cell proliferation was not affected as compared with control cultures ( Figure 3A, B) .
However, cells treated with miR-124 NPs showed a higher number of proliferating neuroblasts (Ki67 + /DCX + ; Figure 3C , E) and a lower number of proliferating astrocyte-like cells (Ki67 + /GFAP + ; Figure 3D , F) when compared with the respective controls. Thus, our results indicate that miR-124 NPs favor neuroblast proliferation while decreasing the proliferation of astrocytic-like cells.
In accordance, others have showed that viral overexpression of miR-124 is able to promote the commitment of type C progenitor cells towards a neuronal fate while reducing the stem/progenitor cell pool [13, 14] . In physiological conditions, the expression of mir-124 is also increased during the transition from progenitors towards mature neuronal cells [13, 14] . 
miR-124 NPs induce neuronal differentiation by repressing key non-neuronal genes.
The ability of miR-124 NPs to induce neuronal differentiation was then assessed. As shown in Figure 4 , miR-124 NPs led to a 2.5-fold increase in the number of mature neurons (NeuN; Figure 4A , B) while reducing to approximately 25% the number of astrocytes (GFAP; Figure 4C , E) as compared with scramble-miR NP-treated cells. No effects were found in terms of oligodendrocyte differentiation (oligodendrocytes transcription factor 2 (Olig2); Figure 4D , F). Although the oligodendrocytic lineage is dependent on Olig2 expression, a subpopulation of stem/progenitor cells also express Olig2 [36] . These data are in accordance with the results shown in Figure 3 . Moreover, Akerblom and colleagues reported an increased number of astrocytes after miR-124
inhibition [14] and Neo and colleagues showed that miR-124 was able to control the choice between neuronal or astrocytic differentiation [37] .
miR-124 targets include several non-neuronal-related genes including Sox9 (Notch downstream effector involved in glial fate specification and in the maintenance of stem cells in an undifferentiated state) [13, 38, 39] and jagged1 (Notch1 ligand involved in stem cell self-renewal) [13, 38, 40] , among others. Therefore, the mRNA and protein levels of Sox9 and Jagged1 (Jag1) were evaluated by qPCR and immunocytochemistry, respectively. As expected, miR-124 NPs induced a reduction of approximately 30% in mRNA ( Figure 5A ) and a reduction of almost 50% in protein levels ( Figure 5B , C, D, E) of both Sox9 and Jagged1. Altogether, our results indicate that miR-124 NPs modulate SVZ cells fate and downregulate Sox9 and Jagged1, leading to a robust enhancement of neurogenesis and a slight reduction in the number of astrocytes. 
miR-124 NPs promote axonogenesis.
Axon formation and neurite outgrowth are essential processes for the maturation and integration of newborn neurons; these processes are dependent on c-Jun N-terminal kinases (JNK) pathway activation [41] . To evaluate the effect of miR-124 NPs on neuronal maturation and axonogenesis, SVZ cells were transfected with miR-124 NPs for 4 h and the activation of SAPK/JNK pathway was analyzed 24 h post-transfection by immunocytochemistry against phospho (P)-JNK, the JNK active form. MiR-124 NPs induced a 1.6 and 2-fold increase in the number ( Figure 6A ) and length ( Figure 6B ) of P-JNK + axons emerging out of the neurospheres, respectively. Accordingly, in miR-124
NP-treated cultures P-JNK immunoreactivity was robust while control cultures showed a more diffuse and weak staining ( Figure 6C ). Also, as reported previously by us, the P-JNK staining co-localized with Tau, a microtubule-associated protein able to modulate the stability of axonal microtubules in mature and immature neurons [29, 30] .
JNK can phosphorylate and activate several transcription factors in the nucleus, including c-Jun, which may transduce cell death signals [42] [43] [44] . As shown in Figure   6C , P-JNK immunoreactivity was localized in Tau-positive axons, but not in the nucleus, suggesting that miR-124 NPs promote axonogenesis instead of inducing apoptosis. Additionally, neither apoptosis nor late-apoptosis/necrosis was induced by 1 µg/mL miR-124 NPs ( Figure 2B , C, D, E). Indeed, growing literature supports a role of JNK in cell proliferation, survival, and differentiation. For instance, it was shown that JNK1 and the JNK pathway-specific scaffold protein, JSAP1, promote neural differentiation of embryonic stem cells [45, 46] . Activated JNK may also foster axonogenesis and neuronal polarization by targeting cytoskeletal proteins, such as the Tau protein [47, 48] .
Our results are also in accordance with a previous report showing that miR-124 is able to control neurite outgrowth during neuronal differentiation presumably by regulating cytoskeleton proteins [15] . Additionally, it has been shown by others that miR-124 promotes neurite elongation in human neuroblastoma and mouse P19 cell lines by repressing Rho-associated coiled-coil forming protein kinase 1 (ROCK1), an upstream repressor of the phosphoinositide 3-kinase (PI3K)/Akt pathway [49] . In sum, the activation of the SAPK/JNK pathway found in Tau-expressing axons suggests that miR- Figure 7B ). Then, to unveil the effect of our NP formulation in a pre-clinical mouse model for PD, mice were subjected to a double stereotaxic injection to deliver 6-OHDA into the right striatum and the NPs into the right lateral ventricle ( Figure 7A ). This mouse model for PD (10 µg 6-OHDA in the striatum) was chosen based in the following parameters: reduced SVZ neurogenesis (about 40% reduction in DCX + /BrdU + cells in the SVZ, Figure 7D ), dopaminergic degeneration (about 50% dopaminergic death in the SN: 48.1 ± 6.1, n=10 mice), functional motor deficits ( Figure 9D) , and low mortality rates (in opposite to models such as involving injections in the SN or in the medial forebrain bundle).
Mice were euthanized 4 weeks after stereotaxic surgeries and the number of neuroblasts (DCX + ), and proliferating neuroblasts (DCX + /BrdU + ) were quantified in the SVZ (Figure 7 ) and in the GCL and GL of the OB (Figure 8 ). First, we found that miR-124 NPs were not able to alter the total number of DCX + ( Figure   7C ) and DCX + /BrdU + cells ( Figure 7D , E-H) in the SVZ of both healthy and 6-OHDA-treated mice as compared with the respective saline group. Nevertheless, the levels of proliferating neuroblasts (DCX + /BrdU + cells) in 6-OHDA-treated mice were approximately 50% lower than in healthy mice. This may indicate a negative influence of striatal dopamine depletion over neuroblast proliferation and/or migration into lesioned regions (striatum) or into the OB. However, the total number of neuroblasts (DCX + ; Figure 7C Figure 1) . Although we do not know the neuronal phenotype generated by DCX + neuroblasts found in the GCL, we do know that the GCL contains mostly SVZ-derived GABAergic interneurons [50, 51] .
In physiological conditions neuroblasts originated in the SVZ migrate through the rostral migratory stream towards the OB. However, upon brain damage, neuroblasts can also migrate towards the lesion replacing damaged or dead neurons [34] . Accordingly, some proliferating neuroblasts (DCX + /BrdU + )
(Supplementary Figure 2) as well as mature neurons (NeuN + /BrdU + ) ( Figure 9A , B, C) were found in the striatum of 6-OHDA-treated mice, demonstrating that DA depletion per se activated endogenous brain repair mechanisms. Importantly, miR-124 NPs further increased the number of mature neurons found in the lesioned striatum of 6-OHDA-treated mice ( Figure 9A , B, C). As expected, the levels of NeuN + /BrdU + cells in the striatum were almost inexistent in healthy mice. Our in vivo data suggest that miR-124 NPs reinforce the migration of SVZderived neurons towards the lesioned striatum of 6-OHDA treated mice, likely as an attempt to promote brain repair.
It is known that unilateral injections of 6-OHDA in mice and/or rats have the advantage, when compared with other PD mice models, of presenting side-biased motor impairments [52, 53] . Apomorphine is a dopamine receptor agonist that at low doses causes contralateral turning by stimulating both supersensitive D1 and D2 receptors preferentially on the denervated side (contralateral side) [54] .
Apomorphine-rotation test is used not only to characterize the extent of lesion but also to detect therapeutic effects. To unveil if our treatment has any impact into the amelioration of PD symptoms in the 6-OHDA-lesioned mice we performed a behavioral analysis based on the apomorphine-rotation test ( Figure 9D ). Two weeks after the stereotaxic injections, apomorphine was administrated subcutaneously and rotation to the contralateral or ipsilateral side registered for 45 min. As expected, healthy mice, both saline and miR-124 NP treated mice, exhibited a net rotation near zero, while 6-OHDA-lesioned saline mice presented a significant increase in the net contralateral rotations that was reversed at some extent in miR-124 NP treated mice ( Figure 9D ). Although any significant differences were found in the levels of dopaminergic neurons in the SN of 6-OHDA-lesioned mice (saline and miR-124 NPs, data not shown), the boost of neurogenesis caused by our formulation seems to partly rescue the motor impairments of 6-OHDA-lesioned mice.
Previous reports showed that miR-124 overexpression promotes neurogenesis and decreases SVZ proliferation in physiological conditions. Moreover, it does not interfere with migration nor OB integration [13, 14] , but it endorses a preferential integration of new neurons into the GCL rather than the GL [14] . Accordingly, we showed that a single intracerebroventricular administration of miR-124 NPs is able to modulate SVZ neurogenesis, culminating in the enrichment of new neurons in the GCL of the OB. Then, we hypothesized that miR-124 NPs are also able to boost neurogenesis in a mouse model for PD. PD pathology can cause neurogenesis impairment despite the controversy on this matter (reviewed by Van den Bern et al, 2013 [55] ). For example, injection of 6-OHDA in mice led to a reduction in SVZ proliferation [56, 57] , yet the levels of neuroblasts in SVZ and RMS were not affected and a higher survival of neurons in the OB was detected [57] . We also observed a reduction in SVZ proliferation caused by 6-OHDA that as neuroprotection [20, 21] or reduction of neuroinflammation [58] [59] [60] . Taken together, our results suggest that miR-124 NPs are an attractive future therapeutic approach to potentiate the endogenous recovery of the injured brain, namely in PD. Results are set to 100%; # displays the difference between 6-OHDA-lesioned saline and miR-124 NPs mice.
Conclusions
To the best of our knowledge, this is the first report showing not only the ability of a NP formulation to modulate the endogenous neurogenic niche in PD but also its ability to ameliorate PD motor symptoms. Notably, we were able to demonstrate the pro-neurogenic potential of miR-124 NPs both in physiologic conditions and in a pre-clinical mouse model for PD. MiR-based therapies have been emerging in the last few years. Indeed, some clinical trials using miR-based therapies are being performed [61] . Nevertheless, one of the major concerns in the translation of miR-based therapies to the clinic is the efficient delivery of these molecules into cells. The physicochemical properties of miR (hydrophilic nature and negative charge) as well as their easy cleavage by nucleases make the transfection efficiency a challenge by itself [22, 23] . We have developed a novel polymeric NP formulation which was efficiently internalized by NSCs, enhanced neurogenesis both in physiological and pathological conditions and can be traced by 19 F MRI technique [26] . The theranostic feature of our NPs makes it an attractive model to future clinical studies and an alternative to the NPs being currently used for MRI clinical application, such as superparamagnetic iron oxide
NPs. Other important feature is the use of Food and Drug Administration (FDA)-approved materials in its composition [26] which can be engineered in terms of surface ligands making its delivery more specific and facilitating the translation to the clinic. Altogether, the NP formulation developed by us can overcome issues related with safety and traceability that other miR-delivery agents such as viral vectors and liposomes cannot [22, 23] . Most importantly, the formulation has already shown to be efficient in the delivery of miR into endothelial cells [26] .
The biological effects of miR delivery previously described were higher than the ones obtained by commercial transfection reagents [26] . 
